Please wait while the formulary information is being retrieved.
KYPROLIS (carfilzomib)
- Multiple myeloma
10 mg intravenous solution
- Dosage information is not available
30 mg intravenous solution
- Dosage information is not available
60 mg intravenous solution
- Dosage information is not available
Multiple myeloma
- Infuse 20 mg/m2 over 10 minute(s) by intravenous route on days 1 and 2 of a 28 day treatment cycle (cycle 1)
- Infuse 27 mg/m2 over 10 minute(s) by intravenous route on days 8, 9, 15 and 16 of a 28 day treatment cycle (cycle 1)
- Infuse 27 mg/m2 over 10 minute(s) by intravenous route on days 1, 2, 8, 9, 15 and 16 of a 28 day treatment cycle (cycles 2-12)
- Infuse 27 mg/m2 over 10 minute(s) by intravenous route on days 1, 2, 15 and 16 of a 28 day treatment cycle (cycles 13 and beyond)
- Infuse 20 mg/m2 over 30 minute(s) by intravenous route on days 1 and 2 of a 28 day treatment cycle (cycle 1)
- Infuse 56 mg/m2 over 30 minute(s) by intravenous route on days 8, 9, 15 and 16 of a 28 day treatment cycle (cycle 1)
- Infuse 56 mg/m2 over 30 minute(s) by intravenous route on days 1, 2, 8, 9, 15 and 16 of a 28 day treatment cycle (cycles 2 and beyond)
- Infuse 56 mg/m2 over 30 minute(s) by intravenous route on days 1, 2, 8, 9, 15 and 16 of a 28 day treatment cycle (cycles 2-12)
- Infuse 56 mg/m2 over 30 minute(s) by intravenous route on days 1, 2, 15 and 16 of a 28 day treatment cycle (cycles 13 and beyond)
- Infuse 15 mg/m2 over 10 minute(s) by intravenous route once
- Infuse 36 mg/m2 over 30 minute(s) by intravenous route once
- Infuse 45 mg/m2 over 30 minute(s) by intravenous route once
- Infuse 70 mg/m2 over 30 minute(s) by intravenous route on days 8 and 15 of a 28 day treatment cycle (cycle 1)
- Infuse 70 mg/m2 over 30 minute(s) by intravenous route on days 1, 8 and 15 of a 28 day cycle (cycles 2 and beyond)
- Infuse 20 mg/m2 over 30 minute(s) by intravenous route once
- None
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Posterior reversible encephalopathy syndrome
Contraindicated
- Abnormal hepatic function tests
- Acute myocardial infarction
- Acute renal failure
- Cardiac arrest
- Chronic heart failure
- Dyspnea
- Hemolytic uremic syndrome
- Herpes zoster
- Hyperbilirubinemia
- Hypertension
- Myocardial ischemia
- Neutropenic disorder
- Peripheral neuropathy
- Pregnancy
- Pulmonary hypertension
- Thrombocytopenic disorder
- Thromboembolic disorder
Severe
Moderate
- Pneumonia
KYPROLIS (carfilzomib)
- Multiple myeloma
- Anemia
- Dyspnea
- Fever
- Hypertension
- Hypokalemia
- Hypomagnesemia
- Leukopenia
- Lymphopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Back pain
- Constipation
- Cough
- Diarrhea
- Fatigue
- Headache disorder
- Insomnia
- Muscle spasm
- Nausea
- Pain
- Peripheral edema
- Peripheral neuropathy
- Upper respiratory infection
- Vomiting
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Acute renal failure
- Chemotherapy-induced hyperuricemia
- Deep venous thrombosis
- Gastroenteritis
- Gastrointestinal hemorrhage
- Heart failure
- Hyperbilirubinemia
- Hypercalcemia
- Hyperkalemia
- Hypersensitivity drug reaction
- Hypoalbuminemia
- Hyponatremia
- Hypophosphatemia
- Hypotension
- Kidney disease with reduction in GFR
- Multiple organ failure
- Pneumonia
- Pulmonary edema
- Pulmonary hypertension
- Pulmonary thromboembolism
- Sepsis
- Septic shock
- Viral infection
- Worsening of chronic heart failure
- Acute abdominal pain
- Angina
- Anorexia
- Arthralgias
- Blurred vision
- Cataracts
- Chest tightness
- Chills
- Delirium
- Dizziness
- Dyspepsia
- Epistaxis
- Erythema
- Facial edema
- Flushing
- General weakness
- Hyperglycemia
- Hyperhidrosis
- Hypesthesia
- Influenza
- Malaise
- Muscle weakness
- Myalgias
- Pain in oropharynx
- Palpitations
- Paresthesia
- Pharyngitis
- Pruritus of skin
- Rhinitis
- Symptoms of anxiety
- Syncope
- Tachycardia
- Toothache
- Urinary tract infection
- Voice change
- Wheezing
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Auditory neurotoxicity
- Cardiac arrest
- Cholestasis
- Chronic heart failure
- Clostridium difficile infection
- Cytomegalovirus disease
- Dehydration
- Enterocolitis
- Gastrointestinal perforation
- Hemolytic uremic syndrome
- Hemorrhage
- Hepatic failure
- Herpes zoster
- Hypertensive crisis
- Interstitial pneumonitis
- Intracranial bleeding
- Myocardial ischemia
- Pericardial effusion
- Pericarditis
- Posterior reversible encephalopathy syndrome
- Progressive multifocal leukoencephalopathy
- Pulmonary hemorrhage
- Reactivation of hepatitis B
- Thromboembolic disorder
- Thrombotic thrombocytopenic purpura
Less Severe
- Acute confusion
- Tinnitus
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Carfilzomib
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Carfilzomib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Carfilzomib
Insuff human data; serious adverse effects possible
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff human data; serious adverse effects possible |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Carfilzomib
General-The incidence of serious adverse drug reactions in elderly over age 64 was higher than in younger patients, ranging from 50-74%. Cardiovascular-Monitor patient for new onset or worsening of preexisting cardiac failure, restrictive cardiomyopathy, myocardial ischemia and myocardial infarction. Immunology- Screen for hepatitis B prior to initiation due to risk of hepatitis B reactivation per European Medicine Association drug safety review.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Multiple myeloma | |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| 0-9 | A-Z |
|---|---|
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
Formulary Reference Tool